Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer

Cancer Chemother Pharmacol. 2018 Sep;82(3):419. doi: 10.1007/s00280-018-3641-5.

Authors

Affiliations

¹ South Texas Accelerated Research Therapeutics (START), 4383 Medical Drive, Suite 4026, San Antonio, TX, USA. [email protected].
² HonorHealth Research Institute, Scottsdale, AZ, USA.
³ South Texas Accelerated Research Therapeutics (START), 4383 Medical Drive, Suite 4026, San Antonio, TX, USA.
⁴ Cancer Medicine Division, MD Anderson Cancer Center, The University of Texas, Houston, TX, USA.
⁵ Eli Lilly and Company, Indianapolis, IN, USA.

Abstract

The original version of this article unfortunately contained a mistake. The co-authors' names were incorrect.

Publication types

Published Erratum